PMID- 36529441
OWN - NLM
STAT- MEDLINE
DCOM- 20230411
LR  - 20230513
IS  - 2213-2201 (Electronic)
VI  - 11
IP  - 4
DP  - 2023 Apr
TI  - Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis.
PG  - 1134-1146
LID - S2213-2198(22)01296-X [pii]
LID - 10.1016/j.jaip.2022.11.036 [doi]
AB  - BACKGROUND: A growing number of studies have shown encouraging results with 
      omalizumab (OMA) as monotherapy and as an adjunct to oral immunotherapy (OMA+OIT) 
      in patients with single/multiple food allergies. OBJECTIVES: To evaluate the 
      efficacy and safety of OMA or OMA+OIT in patients with immunoglobulin E 
      (IgE)-mediated food allergy. METHODS: An extensive literature search (inception 
      to December 31, 2020) was performed to identify randomized, controlled, and 
      observational studies that assessed OMA as monotherapy or OMA+OIT in patients 
      with IgE-mediated food allergy. The outcomes were an increase in tolerated dose 
      of foods, successful desensitization, sustained unresponsiveness, immunological 
      biomarkers, severity of allergic reactions to food, quality of life (QoL), and 
      safety. A P less than .05 was considered significant. RESULTS: In total, 36 
      studies were included. The OMA monotherapy (vs pre-OMA) significantly increased 
      the tolerated dose of multiple foods; increased the threshold of tolerated dose 
      for milk, egg, wheat, and baked milk; improved QoL; and reduced food-induced 
      allergic reactions (all P < .01). The OMA+OIT significantly increased the 
      tolerated dose of multiple foods (vs placebo and pre-OMA), desensitization (vs 
      placebo+OIT and pre-OMA) (all P </= .01), and improved QoL (vs pre-OMA) and 
      immunoglobulin G4 levels (both P < .01). No major safety concerns were 
      identified. CONCLUSIONS: In IgE-mediated food allergy, OMA can help patients 
      consume multiple foods and allow for food dose escalation. As an adjunct to OIT, 
      OMA can also support high-dose desensitization and higher maintenance doses. 
      Further studies are warranted to empirically evaluate the effect of OMA and 
      confirm these findings.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Zuberbier, Torsten
AU  - Zuberbier T
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 
      Allergology and Immunology, Berlin, Germany; Institute of Allergology, Charite - 
      University Medicine Berlin, Corporate Member of Freie University of Berlin and 
      Humboldt University of Berlin, Berlin, Germany. Electronic address: 
      torsten.zuberbier@charite.de.
FAU - Wood, Robert A
AU  - Wood RA
AD  - Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins 
      University School of Medicine, Baltimore, Md.
FAU - Bindslev-Jensen, Carsten
AU  - Bindslev-Jensen C
AD  - Odense Research Centre for Anaphylaxis, Odense University Hospital, Odense, 
      Denmark; Department of Dermatology and Allergy Centre, Odense University 
      Hospital, Odense, Denmark.
FAU - Fiocchi, Alessandro
AU  - Fiocchi A
AD  - Translational Research in Paediatric Specialities Area, Division of Allergy, 
      Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere 
      Scientifico (IRCCS), Rome, Italy.
FAU - Chinthrajah, R Sharon
AU  - Chinthrajah RS
AD  - Sean N. Parker Centre for Allergy and Asthma Research, Stanford University, 
      Stanford, Calif; Division of Pulmonary and Critical Care Medicine, Division of 
      Allergy, Immunology and Rheumatology, Stanford University, Stanford, Calif.
FAU - Worm, Margitta
AU  - Worm M
AD  - Division of Allergy and Immunology, Department of Dermatology, Venerology and 
      Allergy, Charite - University Medicine, Berlin, Germany.
FAU - Deschildre, Antoine
AU  - Deschildre A
AD  - CHU Lille, Pediatric Pulmonology and Allergy Unit, Jeanne de Flandre Hospital, 
      University of Nord de France, Lille, France.
FAU - Fernandez-Rivas, Montserrat
AU  - Fernandez-Rivas M
AD  - Allergy Department, Hospital Clinico San Carlos, Universidad Complutense de 
      Madrid (UCM), Instituto de Investigacion Sanitaria del Hospital Clinico San 
      Carlos (IdISSC), Madrid, Spain.
FAU - Santos, Alexandra F
AU  - Santos AF
AD  - Department of Women and Children's Health (Pediatric Allergy), School of Life 
      Course Sciences, Faculty of Life Sciences and Medicine, King's College London, 
      London, UK; Peter Gorer Department of Immunobiology, School of Immunology and 
      Microbial Sciences, King's College London, London, UK; Children's Allergy 
      Service, Evelina London, Guy's and St Thomas' Hospital, London, UK; Asthma UK 
      Centre in Allergic Mechanisms of Asthma, London, UK.
FAU - Jaumont, Xavier
AU  - Jaumont X
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Tassinari, Paolo
AU  - Tassinari P
AD  - Novartis Pharma AG, Basel, Switzerland.
LA  - eng
GR  - MR/T032081/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20221215
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Allergens)
SB  - IM
MH  - Humans
MH  - Animals
MH  - *Omalizumab/therapeutic use
MH  - Quality of Life
MH  - Immunoglobulin E
MH  - Desensitization, Immunologic/methods
MH  - Administration, Oral
MH  - *Food Hypersensitivity/drug therapy
MH  - Allergens
MH  - Milk
OTO - NOTNLM
OT  - Desensitization
OT  - Food (allergen) tolerance
OT  - IgE-mediated food allergy
OT  - Meta-analysis
OT  - Omalizumab
OT  - Oral immunotherapy
OT  - Sustained unresponsiveness
EDAT- 2022/12/19 06:00
MHDA- 2023/04/11 06:42
CRDT- 2022/12/18 19:26
PHST- 2022/07/11 00:00 [received]
PHST- 2022/11/14 00:00 [revised]
PHST- 2022/11/26 00:00 [accepted]
PHST- 2023/04/11 06:42 [medline]
PHST- 2022/12/19 06:00 [pubmed]
PHST- 2022/12/18 19:26 [entrez]
AID - S2213-2198(22)01296-X [pii]
AID - 10.1016/j.jaip.2022.11.036 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2023 Apr;11(4):1134-1146. doi: 
      10.1016/j.jaip.2022.11.036. Epub 2022 Dec 15.